Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 7;15(3):945-947.
doi: 10.14336/AD.2023.0819.

Reduced Salivary Lactoferrin Levels in Early-Onset Alzheimer's Disease

Desireé Antequera  1 , Laura Carrero  2 , Marta Gonzalez-Sanchez  2 , José Luis Cantero  3 , Gorka Orive  4 , Cristina Municio  2 , Eva Carro  1
Affiliations

Reduced Salivary Lactoferrin Levels in Early-Onset Alzheimer's Disease

Desireé Antequera et al. Aging Dis. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement

Dr. Carro and Dr. Orive are co-founders of Geroa Diagnostics. No other disclosures were reported.

Figures

Figure 1.
Figure 1.
Salivary lactoferrin levels in control, EOAD, and LOAD groups. (A) Plots for all four-participant groups with median lines added for each group. Values for the mean ± SD are given. Differences between groups were assessed using one-way ANOVA followed by Tukey test (*p < 0.05, ****p < 0.0001). (B, C) ROC curves and their corresponding areas under the curve (AUCs) to differentiate between (B) EOAD patients and younger controls, and (C) LOAD patients and older controls. (D) Correlation between age and salivary levels of lactoferrin in AD patients using the Spearman rank-order test. Abbreviations: EOAD, early-onset Alzheimer’s disease; LOAD, late-onset Alzheimer’s disease; ROC, receiver operating characteristic.
See this image and copyright information in PMC

References

    1. Carro E, Bartolomé F, Bermejo-Pareja F, Villarejo-Galende A, Molina JA, Ortiz P, et al. (2017). Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin. Alzheimers Dement (Amst), 8:131-138. - PMC - PubMed
    1. Bermejo-Pareja F, Del Ser T, Valentí M, de la Fuente M, Bartolome F, Carro E (2020). Salivary lactoferrin as biomarker for Alzheimer's disease: Brain-immunity interactions. Alzheimers Demen, 16:1196-1204. - PMC - PubMed
    1. González-Sánchez M, Bartolome F, Antequera D, Puertas-Martín V, González P, Gómez-Grande A, et al. (2020). Decreased salivary lactoferrin levels are specific to Alzheimer's disease. EBioMedicine, 57:102834. - PMC - PubMed
    1. Reseco L, Atienza M, Fernandez-Alvarez M, Carro E, Cantero JL (2021). Salivary lactoferrin is associated with cortical amyloid-beta load, cortical integrity, and memory in aging. Alzheimers Res Ther, 13:150. - PMC - PubMed
    1. Tort-Merino A, Falgàs N, Allen IE, Balasa M, Olives J, Contador J, et al. (2022). Early-onset Alzheimer's disease shows a distinct neuropsychological profile and more aggressive trajectories of cognitive decline than late-onset. Ann Clin Transl Neurol, 9:1962-1973. - PMC - PubMed

Publication types

LinkOut - more resources